New small-molecule drug to lower cholesterol
PCSK9 inhibitors are the second most popular class of cholesterol-lowering medications after statins. PCSK9 inhibitors are highly effective in removing excess cholesterol from blood. However, unlike statins which can be taken orally, PCSK9 inhibits must be administered by injection, which makes them difficult to use.
Longevity. Technology: High cholesterol levels can increase your risk of heart disease and circulatory disorders such as stroke, heart attack and vascular dementia. But a recent study by investigators from University Hospitals and Case Western Reserve University School of Medicine reveals a small-molecule oral drug that lowers PCSK9 and cholesterol in animal models 70%. The findings, published in Cell Reports represent an unexplored strategy for managing cholesterol. They may also have an impact on cancer treatments.
The number one killer in the world is cardiovascular disease, so it comes as no surprise that there’s a lot of research being done on potential therapeutic options. Just last week, we examined Cyclarity’s rationally designed cyclodextrin molecule that can remove arterial plaques by clearing non-degradable and oxidized cholesterol. It can also be used with statins to provide a broad spectrum approach. Next week we will be releasing our report on Cyclarity’s new platform. Stay tuned!
Source:
